

19 November 2025

EVE Signs Telehealth Services Agreement with hubMed

- National Patient Support Program to assist patients prescribed EVE's products for key women's and men's health conditions
- Expands EVE's telehealth partners following the launch of Dyspro™ and upcoming launch of Libbo™
- Program designed to strengthen continuity of care and patient confidence during treatment
- Provides patients with accessible telehealth consultations delivered by independent clinicians

EVE Health Group Limited (ASX: EVE, EVE or the Company) is pleased to announce that it has entered into a Patient Support Telehealth Services Agreement with hubMed Pty Ltd, a leading provider of telehealth services in Australia. The agreement establishes a nationwide Patient Support Program designed to enhance the safety, quality and continuity of care for patients prescribed EVE's therapeutic products in women's and men's health, including Dyspro™ for dysmenorrhoea and Libbo™ for erectile dysfunction.

Enhancing support across women's and men's health

Improving continuity of care is critical in both women's and men's health, where conditions often go under diagnosed and under managed. Many patients require structured follow up to support adherence, address symptoms early and reinforce clinical guidance in a timely manner.

The hubMed program will provide regular touch points with Registered Nurses who can reinforce safe use, triage concerns within scope and communicate with the patient's usual treating practitioner when clinically necessary. This approach supports better real world outcomes and complements the care provided through traditional medical channels.

EVE Chief Executive Officer, Damian Wood, said: "Women's and men's health conditions are often overlooked, and patients benefit greatly from reliable follow up and trusted clinical support. This partnership strengthens our ability to provide that support. hubMed has a strong clinical governance framework and a model that helps patients stay informed, confident and connected to their treating practitioners. It is an important step in delivering better outcomes for patients who are prescribed our therapies."

hubMed Managing Director, Jessica Stewart said: "Our Registered Nurses have significant experience supporting patients in areas where continuity of care is especially important. We are pleased to partner with EVE on a program that prioritises patient wellbeing, safety and communication with prescribers. This model helps ensure that patients feel supported throughout their treatment journey."

Material Terms of the Agreement

The agreement has an initial term of twelve months and then continues on a rolling twelve month basis unless terminated by either party. The arrangement is non exclusive and does not impose any long term commitment or minimum activity levels.

EVE pays a service fee to hubMed monthly based on the number of patient support interactions delivered during the month. There are no upfront fees, fixed charges, guaranteed volumes or minimum number of interactions required.

Dysmenorrhoea and endometriosis: a substantial women's health burden

Dysmenorrhoea affects the majority of women of reproductive age. A recent Australian study found that 77 percent of women aged 18 to 44 experience disruptive menstrual symptoms, with almost half reporting missed days of work or study¹. The economic burden of menstrual symptoms in Australia is estimated at approximately AUD 14.2 billion per year.¹

More severe cases may be associated with endometriosis, which affects up to 10 percent of reproductive age women. The annual cost per woman with chronic pelvic pain can exceed USD 16,000, with lost productivity accounting for 75 to 84 percent of the total burden.²

Dyspro has been developed to address this significant unmet need under the supervision of authorised prescribers. The hubMed Patient Support Program will provide scheduled Registered Nurse follow up to help ensure adherence, reinforce correct use and provide early support for symptom related concerns within scope.

Erectile dysfunction: a common and often under treated men's health condition

Erectile dysfunction affects one in five men over the age of 18 and up to 40 percent of men over 40³. The condition impacts wellbeing, confidence and relationships, yet remains under treated due to stigma, delayed help seeking and inconsistent follow up.

Libbo, EVE's oral dissolving film for ED, has been designed to offer prescribers a modern dosage form that may support better adherence and patient acceptance. Through hubMed, men prescribed Libbo will have access to structured Registered Nurse contact to support correct use, triage non urgent issues within scope and escalate clinical matters to prescribers when appropriate.

Expansion of Patient Support Platforms

As part of the support activities for the Dyspro™ launch, the Company recently introduced Reclaim My Cycle (www.reclaimmycycle.com), an online community and education platform designed to empower women managing dysmenorrhoea and endometriosis. The platform combines patient friendly education and materials to support awareness, engagement and informed clinical conversations.

Building on this approach, EVE is preparing the rollout of additional support platforms focused on men's health as part of the upcoming Libbo™ launch. These sites will provide clear guidance for

¹ Mardon A.K. et al. *Problematic Periods Costing Young Women—The Impact of Menstrual Symptoms on Work and Study*. *Australian and New Zealand Journal of Obstetrics and Gynaecology*, 2024. <https://obgyn.onlinelibrary.wiley.com/doi/10.1111/ajo.13926>

² Armour M. et al. *The cost of illness and economic burden of endometriosis and chronic pelvic pain in Australia: A national online survey*. <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0223316> Figures in Armour et al. (2019) were originally reported in 2017 International dollars (Int \$), using purchasing power parity (PPP) to approximate US dollar values. These are expressed in USD here for clarity.

³ Prevalence and Risk Factors for Erectile Dysfunction in the US, *The American Journal of Medicine*, vol — (2006), [https://www.amjmed.com/article/S0002-9343\(06\)00689-9/fulltext](https://www.amjmed.com/article/S0002-9343(06)00689-9/fulltext)

men managing erectile dysfunction. The expanded digital ecosystem is designed to create consistent, evidence informed support across both women's and men's health and to strengthen the overall launch pathway for EVE's therapeutic products.

Authorised for release by the Board of Directors.

Company enquiries

+61 8 6465 5500

info@evehealthgroup.com.au

About EVE Health Group

EVE Health Group (ASX: EVE) is an Australian life sciences company focused on developing and commercialising innovative pharmaceutical solutions in high-growth therapeutic areas. The company's lead assets include Dyspro, a fast-acting cannabinoid-based pastille targeting dysmenorrhoea and endometriosis, and Libbo, an oral dissolving film for erectile dysfunction designed to deliver rapid onset and improved patient convenience. Both products leverage EVE's proprietary formulation and delivery technologies to enhance bioavailability and clinical outcomes, representing near-term commercial opportunities in large, underserved global markets.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.

About hubMed

hubMed is an Australian telehealth provider focused on making healthcare more convenient, accessible and patient centred. The company connects individuals with high quality telehealth services that support a wide range of health priorities and everyday clinical needs. hubMed's model is designed to give patients timely access to care from the comfort of their home or workplace, reducing barriers to treatment and improving continuity of care in partnership with healthcare practitioners across Australia.

For further information, please visit www.hubmed.com.au